5 Best Gene Therapy Stocks to Buy in 2026

3. Passage Bio Inc (NASDAQ:PASG)

Stock Upside Potential: 125.73%

Number of Hedge Fund Holders: 7

Passage Bio Inc (NASDAQ:PASG) is one of the best gene therapy stocks to buy in 2026. While the stock is down around 50% year-to-date, analysts see it surging 125% over the next 12 months.

On April 20, Passage Bio said it was reviewing its strategic alternatives to maximize shareholder value. It has tapped Wedbush PacGrow as a financial advisor to help with this task.

Passage Bio’s lead product candidate is PBFT02. The company is developing PBFT02 as a potential treatment for frontotemporal dementia. A Phase 1/2 trial of this gene therapy is ongoing.

Interim data from that trial suggested that PBFT02 may slow disease progression in patients with frontotemporal dementia. The management cited improvements in both brain atrophy and plasma neurofilament levels, and noted that these two are well-established biomarkers of disease progression.

However, when the company met with the FDA, the regulator indicated that it would require a randomized controlled trial for registrational purposes. Passage Bio’s management said that in light of this outcome as well as taking into account logistical and financial challenges, they are viewing the next steps for the PBFT02 program as and the company.

Pennsylvania-based Passage Bio Inc (NASDAQ:PASG) is a genetic medicines company. Passage Bio is developing gene therapies for central nervous system disorders. Its programs target hard-to-treat, devastating diseases.

1281292 - 11759070 - 1